S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:TCON

TRACON Pharmaceuticals (TCON) Stock Forecast, Price & News

$1.77
-0.09 (-4.84%)
(As of 05/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.74
$1.89
50-Day Range
$1.64
$2.86
52-Week Range
$1.61
$7.42
Volume
45,929 shs
Average Volume
93,708 shs
Market Capitalization
$35.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.82
30 days | 90 days | 365 days | Advanced Chart
Receive TCON News and Ratings via Email

Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TRACON Pharmaceuticals logo

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCON
Employees
19
Year Founded
N/A

Sales & Book Value

Annual Sales
$350 thousand
Book Value
$0.14 per share

Profitability

Net Income
$-28.67 million
Pretax Margin
-9,559.54%

Debt

Price-To-Earnings

Miscellaneous

Free Float
15,401,000
Market Cap
$35.54 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/11/2022
Today
5/21/2022
Next Earnings (Estimated)
8/10/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.47 out of 5 stars

Medical Sector

151st out of 1,416 stocks

Biological Products, Except Diagnostic Industry

20th out of 210 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -













TRACON Pharmaceuticals (NASDAQ:TCON) Frequently Asked Questions

Is TRACON Pharmaceuticals a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRACON Pharmaceuticals stock.
View analyst ratings for TRACON Pharmaceuticals
or view top-rated stocks.

When is TRACON Pharmaceuticals' next earnings date?

TRACON Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for TRACON Pharmaceuticals
.

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) announced its quarterly earnings results on Wednesday, May, 11th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.07. During the same quarter in the previous year, the firm earned ($0.33) EPS.
View TRACON Pharmaceuticals' earnings history
.

What price target have analysts set for TCON?

3 equities research analysts have issued 1-year target prices for TRACON Pharmaceuticals' shares. Their forecasts range from $10.00 to $13.00. On average, they expect TRACON Pharmaceuticals' stock price to reach $11.50 in the next twelve months. This suggests a possible upside of 549.7% from the stock's current price.
View analysts' price targets for TRACON Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are TRACON Pharmaceuticals' key executives?
TRACON Pharmaceuticals' management team includes the following people:
  • Dr. Charles P. Theuer M.D., Ph.D., CEO, Pres & Director (Age 58, Pay $827.53k)
  • Mr. Scott B. Brown CPA, M.S., Chief Financial Officer (Age 41, Pay $459.21k)
  • Mr. Mark C. Wiggins M.B.A., Chief Bus. Officer (Age 66, Pay $506.25k)
  • Ms. Bonne Adams, Exec. VP of Clinical Operations (Age 45)
  • Mr. Shahe Garabedian, Sr. VP & Head of Quality Assurance
  • Dr. James L. Freddo, Chief Medical Officer (Age 67)
  • Mr. Ya Huang, Exec. Director of Statistical Programming
  • Dr. Brenda Marczi Pharm.D., Pharmd Mba, Sr. VP of Regulatory Affairs
What other stocks do shareholders of TRACON Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX).

When did TRACON Pharmaceuticals IPO?

(TCON) raised $47 million in an IPO on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel served as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

What is TRACON Pharmaceuticals' stock symbol?

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

Who are TRACON Pharmaceuticals' major shareholders?

TRACON Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.97%), Bank of New York Mellon Corp (0.72%), Renaissance Technologies LLC (0.15%), Jane Street Group LLC (0.05%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own TRACON Pharmaceuticals stock include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc, Saundra L Pelletier and Scott B Brown.
View institutional ownership trends for TRACON Pharmaceuticals
.

Which institutional investors are selling TRACON Pharmaceuticals stock?

TCON stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Vanguard Group Inc..
View insider buying and selling activity for TRACON Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying TRACON Pharmaceuticals stock?

TCON stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Jane Street Group LLC, and Simplex Trading LLC. Company insiders that have bought TRACON Pharmaceuticals stock in the last two years include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc, Saundra L Pelletier, and Scott B Brown.
View insider buying and selling activity for TRACON Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of TRACON Pharmaceuticals?

Shares of TCON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TRACON Pharmaceuticals' stock price today?

One share of TCON stock can currently be purchased for approximately $1.77.

How much money does TRACON Pharmaceuticals make?

TRACON Pharmaceuticals has a market capitalization of $35.54 million and generates $350 thousand in revenue each year. The biopharmaceutical company earns $-28.67 million in net income (profit) each year or ($1.84) on an earnings per share basis.

How many employees does TRACON Pharmaceuticals have?

TRACON Pharmaceuticals employs 19 workers across the globe.

What is TRACON Pharmaceuticals' official website?

The official website for TRACON Pharmaceuticals is www.traconpharma.com.

How can I contact TRACON Pharmaceuticals?

TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at (858) 550-0780, via email at [email protected], or via fax at 858-550-0786.

This page was last updated on 5/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.